Evidence map›Paper›PMID 37924455›Full record

SynthesisClinical and experimental medicine2023

A systematic review regarding the prevalence of malignancy in patients with the hyper-IgE syndrome.

Tayebeh Mohammadi, Gholamreza Azizi, Hosein Rafiemanesh, Pouria Farahani, Matineh Nirouei, Marzieh Tavakol

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Clinical and experimental medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Case Report:Frontiers in pediatrics · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. The genetics of hyper IgE syndromes.Frontiers in immunology · 2025
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Tayebeh MohammadiNon-Communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran.
Gholamreza AziziNon-Communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran.
Hosein RafiemaneshNon-Communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran.
Pouria FarahaniNon-Communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran.
Matineh NiroueiAlborz University of Medical Sciences, Karaj, Iran.
Marzieh TavakolNon-Communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran. marziyeh.tavakol@gmail.com.
Jahrom University of Medical Sciences · IRAlborz University of Medical Sciences

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The hyper-immunoglobulin E syndrome (HIES) is a primary immunodeficiency disease originally described as Job syndrome. The fundamental causative variant of the HIES is an autosomal dominant mutation in the signal transducer and activator of transcription 3 (STAT3) gene. It is characterized by recurrent staphylococcal cold skin abscess, sinopulmonary infection, eczema, head and face anomalies, frequent bone fractures, eosinophilia and extremely high serum IgE levels (IgE ≥ 2000 IU/mL). However, multiple other genetic defects are also known as HIES-like disorders. Apart from infectious manifestations, STAT3, DOCK8 and TYK2 gene mutations are associated with various malignancies. The most common malignancies reported in these patients are lymphomas, including Hodgkin's and non-Hodgkin's lymphomas (NHL) of B and T cells. This systematic review aimed to investigate the prevalence of malignancies in HIES and the factors associated with malignancy in these patients. In this survey, all articles published until April 1st, 2023, in Scopus, PubMed and Web of Science databases based on three groups of keywords related to HIES syndrome and malignancy were reviewed by three different researchers. Finally, 26 articles were evaluated from which 24 papers were meta-analyzed. In the current study, the demographic information of 1133 patients with HIES, which was mentioned in 24 articles enrolled in the project, was collected, and the information related to patients who had malignancy was analyzed and meta-analyzed. A total of 96 patients out of 1133 studied patients had at least one type of malignancy, the overall prevalence of malignancies reported in the articles was 6.5% (95% confidence interval 4.1-9%), and the total prevalence of malignancy in patients with NHL type and patients with squamous cell carcinoma (SCC) was 2.9% (95% confidence interval 1.7-4.4%) and 2.2% (95% confidence interval 0.3-4.1%), respectively. The results of this study indicated that in 6.5% of cases, HIES was complicated with malignancy, and considering the higher rate of these malignancies in women as well as in DOCK8 mutation sufferers, it is necessary for physicians to be aware of this association and includes malignancy screening in follow-up and periodic examinations of these patients. Indeed, more studies in this field will help to clarify the precise figures and predisposing factors of the relationship between HIES and malignancy.

Indexed as

Job SyndromeLymphomaNeoplasmsFemaleGuanine Nucleotide Exchange FactorsHumansImmunoglobulin EMutationPrevalenceDOCK8 protein, humanGuanine Nucleotide Exchange FactorsImmunoglobulin EHIES syndromeIgEJob syndromeMalignancyPrimary immunodeficiency

Identifiers

PMID37924455
OpenAlexW4388339603

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.